Sponsor Pipeline

Telix Pharmaceuticals (Innovations) Pty Limited Clinical Trial Pipeline

Data updated daily from ClinicalTrials.gov — last refresh 2026-08-16
8
Active Trials
7
Recruiting
5
Phase 3
3
Disease Areas
9
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-08-14 NCT05450744
131I-TLX-101 for Treatment of Newly Diagnosed Glioblastoma (IPAX-2)
Enrollment closed, study ongoing
2026-08-14 NCT05450744
131I-TLX-101 for Treatment of Newly Diagnosed Glioblastoma (IPAX-2)
date change Primary completion pushed: 2026-06 -> 2027-06
2026-08-14 NCT05450744
131I-TLX-101 for Treatment of Newly Diagnosed Glioblastoma (IPAX-2)
date change Completion pushed: 2026-06 -> 2027-06
2026-08-12 NCT07100730
Study of TLX101-Tx Plus Standard of Care (SoC) Versus SoC Alone for the Treatment of…
Trial sites expanded: 4 -> 9 locations
2026-08-02 NCT05847348
68Ga-PSMA-11 Efficacy in Detecting BCR Prostate Cancer in Chinese Patients
overall status: Recruiting → Unknown
2026-07-24 NCT07052214
PSMA PET Combined With MRI for the Detection of PCa
Enrollment increased: 204 -> 338 participants
2026-07-24 NCT07052214
PSMA PET Combined With MRI for the Detection of PCa
Trial sites expanded: 1 -> 18 locations
2026-07-24 NCT07052214
PSMA PET Combined With MRI for the Detection of PCa
date change Primary completion pushed: 2026-06 -> 2027-01
2026-07-24 NCT07052214
PSMA PET Combined With MRI for the Detection of PCa
date change Completion pushed: 2026-11 -> 2027-04
Active Trials by Phase
Phase 3
5
Phase 1
3
Active Trials
NCT IDTitleConditionStatus
Phase 3
NCT06750419 89Zr-TLX250 for PET/CT Imaging of ccRCC - ZIRCON-CP Study Clear Cell Renal Cell Carcinoma Recruiting
NCT07197580 Phase 3 Study to Assess Safety and Efficacy of 177Lu-TLX250 in Advanced Relapsed or… ccRCC Recruiting
NCT06520345 The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT… Metastatic Castration-resistant Prostate Cancer Recruiting
NCT07052214 PSMA PET Combined With MRI for the Detection of PCa PCA Recruiting
NCT07100730 Study of TLX101-Tx Plus Standard of Care (SoC) Versus SoC Alone for the Treatment of… Neoplastic Disease Recruiting
Phase 1
NCT05868174 Combination of 177Lu-TLX250 and Peposertib in Patients With Carbonic Anhydrase IX… Solid Tumor, Adult Recruiting
NCT07197645 Samarium Optimized for Long-lasting Analgesia in Cancerous End-stage Bone Pain Bone Pain Recruiting
NCT05450744 131I-TLX-101 for Treatment of Newly Diagnosed Glioblastoma (IPAX-2) Neoplastic Disease Active, Not Recruiting
Disease Areas
Get alerts when Telix Pharmaceuticals (Innovations) Pty Limited's trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free